Skip to search formSkip to main contentSkip to account menu

bendamustine

Known as: 5-(Bis(2-chloroethyl)amino)-1-methyl-2-benzimidazolebutyric Acid, Bendamustin 
The active ingredient in a drug that is used to treat chronic lymphocytic leukemia (CLL), to treat slow-growing B-cell non-Hodgkin lymphoma (NHL… 
National Institutes of Health

Related topics

Related topics

7 relations
Alkylating Activity [MoA]NCIt Antineoplastic Agent TerminologySDX-105bendamustine hydrochloride 25 MG Injection [Treanda]

Narrower (3)

RibomustineTreandabendamustine hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL Interim Results of a Phase 3 Randomized, Double-blind Placebo-Controlled Trial
(BR) has been a standard of care for the management of patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL… 
2017
2017
Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia
2017
2017
Ibrutinib is an effective treatment for B‐cell prolymphocytic leukaemia
Amin Rahemtulla Kikkeri N. Naresh Department of Cellular and Molecular Pathology, Imperial College Healthcare NHS Trust… 
2014
2014
Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy
Background Patients (pts) with Hodgkin lymphoma (HL) who have relapsed/refractory disease after frontline therapy typically… 
Highly Cited
2012
Highly Cited
2012
Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone
PurposeRenal failure is a frequent complication of multiple myeloma (MM) and, if present at diagnosis, a considerable risk factor… 
Review
2011
Review
2011
Maintenance therapy for B-chronic lymphocytic leukemia.
Although modern treatment options for B-chronic lymphocytic leukemia (CLL) produce high response rates, virtually all patients… 
Review
2011
Review
2011
Bendamustine: mechanism of action and clinical data.
Bendamustine is a chemotherapeutic agent that displays a unique pattern of cytotoxicity compared with conventional alkylating… 
Review
2010
Review
2010
Therapy of chronic lymphocytic leukaemia.
Review
2006
Review
2006
New directions in the treatment of mantle cell lymphoma: an overview.
Mantle cell lymphoma (MCL) is one of the most challenging lymphomas to treat. In the first-line setting, high-dose therapy (HDT… 
Highly Cited
1998
Highly Cited
1998
Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study
Abstract A phase II pilot study of bendamustine as salvage treatment in patients with advanced breast cancer was performed to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)